Boehringer and Lilly present positive cardiovascular data for Jardiance
Boehringer Ingelheim and Eli Lilly (NYSE: LLY) have released positive initial results from the real-world EMPRISE study examining cardiovascular outcomes related to Jardiance (empagliflozin).
The study shows treatment with Jardiance was associated with a 44% relative risk reduction in hospitalization for heart failure (HHF), compared with dipeptidyl peptidase-4 (DPP-4) inhibitors.
The study looked at around 35,000 people with type 2 diabetes, and support findings from the EMPA-REG OUTCOME trial, which showed a 35% relative risk reduction in HHF compared with placebo, when added to standard of care.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze